Autologous Cell Therapy Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
The Global Autologous Cell Therapy Market Size accounted for USD 6.1 Billion in 2022 and is projected to achieve a market size of USD 34.8 Billion by 2032 growing at a CAGR of 19.1% from 2023 to 2032.
Autologous Cell Therapy Market Highlights
- Global autologous cell therapy market revenue is expected to increase by USD 34.8 Billion by 2032, with a 19.1% CAGR from 2023 to 2032
- North America region led with more than 41% of autologous cell therapy market share in 2022
- Asia-Pacific autologous cell therapy market growth will record a CAGR of around 20% from 2023 to 2032
- According to ClinicalTrials.gov, there are currently over 1,500 clinical trials registered for autologous cell therapy
- By source, the bone marrow segment dominated the global market and generated more than 42% of the revenue share in 2022
- By application, the cancer segment has recorded more than 21% of the revenue share in 2022
- Growing demand for personalized medicine, drives the autologous cell therapy market value
Autologous cell therapy is a type of regenerative medicine that involves the use of a patient's own cells to repair or replace damaged tissue. This approach offers a number of advantages over other treatments, as the patient's own cells are less likely to be rejected by the immune system and can be customized to meet their specific needs. Autologous cell therapy is used to treat a wide range of conditions, including cancer, cardiovascular disease, and autoimmune disorders.
The autologous cell therapy market has experienced significant growth in recent years, as advances in technology have made it possible to produce and use these therapies more efficiently and effectively. The market is expected to continue to grow in the coming years, driven by factors such as an aging population, the increasing prevalence of chronic diseases, and the need for more effective and personalized treatments. In addition, ongoing research and development efforts are likely to result in the introduction of new and innovative autologous cell therapies in the years ahead.
Global Autologous Cell Therapy Market Trends
Market Drivers
- Increasing prevalence of chronic diseases
- Growing demand for personalized medicine
- Advancements in technology for cell culture and genetic engineering
- Aging population and longer life expectancy
- Favorable government regulations and funding for research
Market Restraints
- High costs associated with cell therapy treatments
- Limited availability of trained healthcare professionals
Market Opportunities
- Expansion of applications for existing cell therapy treatments
- Increasing collaboration between industry leaders and academic researchers
Autologous Cell Therapy Market Report Coverage
| Market | Autologous Cell Therapy Market |
| Autologous Cell Therapy Market Size 2022 | USD 6.1 Billion |
| Autologous Cell Therapy Market Forecast 2032 | USD 34.8 Billion |
| Autologous Cell Therapy Market CAGR During 2023 - 2032 | 19.1% |
| Autologous Cell Therapy Market Analysis Period | 2020 - 2032 |
| Autologous Cell Therapy Market Base Year | 2022 |
| Autologous Cell Therapy Market Forecast Data | 2023 - 2032 |
| Segments Covered | By Source, By Application, By End-use, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Vericel Corporation, Kite Pharma, Novartis AG, Spark Therapeutics, Organogenesis Inc., bluebird bio, Osiris Therapeutics, Inc., Fibrocell Science, Inc., JCR Pharmaceuticals Co., Ltd., KolonTissueGene, Inc., MEDIPOST Co., Ltd., and TiGenix NV. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Autologous cell therapy is a type of regenerative medicine that uses a patient's own cells to repair or replace damaged tissue. This approach offers a number of benefits, including reduced risk of rejection by the immune system and the ability to customize the treatment to the patient's specific needs. Autologous cell therapy involves harvesting cells from the patient's body, then manipulating and re-implanting them in order to stimulate healing or regeneration. There is a wide range of applications for autologous cell therapy, including the treatment of cancer, cardiovascular disease, autoimmune disorders, and tissue injuries. In cancer treatment, autologous cell therapy is often used to harvest and modify immune cells to better recognize and attack cancer cells. In cardiovascular disease, autologous stem cells may be used to promote the regeneration of damaged heart tissue. In tissue injuries, such as burns or wounds, autologous skin cells may be used to promote healing and reduce scarring.
The autologous cell therapy market has been experiencing significant growth in recent years, and this trend is expected to continue in the coming years. One of the major drivers of this growth is the increasing prevalence of chronic diseases such as cancer, cardiovascular disease, and autoimmune disorders. As the population ages and the incidence of these diseases continue to rise, there is a growing need for more effective and personalized treatments. Autologous cell therapy offers a promising solution, as it uses a patient's own cells to repair or replace damaged tissue, minimizing the risk of rejection and potentially improving outcomes.
Autologous Cell Therapy Market Segmentation
The global autologous cell therapy market segmentation is based on source, application, end-use, and geography.
Autologous Cell Therapy Market By Source
- Bone Marrow
- Mesenchymal Stem Cells
- Epidermis
- Chondrocytes
- Haematopoietic Stem Cells
- Others
According to the autologous cell therapy industry analysis, the bone marrow segment accounted for the largest market share in 2022. Bone marrow is a rich source of stem cells, which can be used to treat a variety of conditions, including cancer, immune disorders, and blood disorders. As a result, bone marrow transplants have become a standard treatment option for many of these conditions. Advancements in technology for bone marrow collection, processing, and transplantation have further fueled the growth of the bone marrow segment. The development of minimally invasive bone marrow harvesting techniques, such as peripheral blood stem cell mobilization and bone marrow aspiration, has made the process less painful and more accessible to patients. Furthermore, the ongoing research and development in the field of bone marrow cell therapy are expected to continue to drive growth in this segment.
Autologous Cell Therapy Market By Application
- Cancer
- Cardiovascular Disorders
- Neurodegenerative Disorders
- Autoimmune Disorders
- Wound Healing
- Orthopedics
- Others
In terms of applications, the cancer segment is expected to witness significant growth in the coming years. Autologous cell therapy has emerged as a promising treatment option for cancer patients, as it offers a targeted and personalized approach to treatment. In this approach, a patient's own cells are genetically modified to produce anti-cancer agents or to enhance the immune system's ability to fight cancer cells. The use of autologous cell therapy in cancer treatment has been particularly successful in treating blood cancers such as leukemia and lymphoma. For instance, chimeric antigen receptor (CAR) T-cell therapy, a type of autologous cell therapy, has been approved by the FDA for the treatment of certain types of blood cancers. Advancements in technology for cell culture and genetic engineering are further driving growth in the cancer segment.
Autologous Cell Therapy Market By End-use
- Hospitals & Clinics
- Academics & Research
- Ambulatory Centers
- Others
According to the autologous cell therapy market forecast, the academics & research segment is expected to witness significant growth in the coming years. Academic and research institutions play a significant role in advancing the field of regenerative medicine and developing new and innovative autologous cell therapies. These institutions conduct research and development activities to explore new applications of autologous cell therapy and to improve existing therapies. They also collaborate with industry leaders to bring these therapies to the market and make them available to patients. Moreover, academic and research institutions receive funding from governments, foundations, and private organizations to support their research and development activities.
Autologous Cell Therapy Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Autologous Cell Therapy Market Regional Analysis
North America dominates the autologous cell therapy market for several reasons. One of the main factors driving this dominance is the presence of a large number of leading pharmaceutical and biotechnology companies in the region, many of which are investing heavily in the development of autologous cell therapy products. This has resulted in the availability of a wide range of autologous cell therapy products, giving North America a significant advantage in the market. Another factor contributing to North America's dominance in the autologous cell therapy market is the region's well-established healthcare infrastructure and high healthcare spending. The region has a well-developed healthcare system that provides access to cutting-edge medical technology and treatments, including autologous cell therapy. Moreover, the high healthcare spending in North America means that patients have greater access to these treatments, further fueling the growth of the market.
Autologous Cell Therapy Market Player
Some of the top autologous cell therapy market companies offered in the professional report include Vericel Corporation, Kite Pharma, Novartis AG, Spark Therapeutics, Organogenesis Inc., bluebird bio, Osiris Therapeutics, Inc., Fibrocell Science, Inc., JCR Pharmaceuticals Co., Ltd., KolonTissueGene, Inc., MEDIPOST Co., Ltd., and TiGenix NV.
Frequently Asked Questions
What was the market size of the global autologous cell therapy in 2022?
The market size of autologous cell therapy was USD 6.1 Billion in 2022.
What is the CAGR of the global autologous cell therapy market from 2023 to 2032?
The CAGR of autologous cell therapy is 19.1% during the analysis period of 2023 to 2032.
Which are the key players in the autologous cell therapy market?
The key players operating in the global market are including Vericel Corporation, Kite Pharma, Novartis AG, Spark Therapeutics, Organogenesis Inc., bluebird bio, Osiris Therapeutics, Inc., Fibrocell Science, Inc., JCR Pharmaceuticals Co., Ltd., KolonTissueGene, Inc., MEDIPOST Co., Ltd., and TiGenix NV.
Which region dominated the global autologous cell therapy market share?
North America held the dominating position in autologous cell therapy industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of autologous cell therapy during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global autologous cell therapy industry?
The current trends and dynamics in the autologous cell therapy industry include increasing prevalence of chronic diseases, growing demand for personalized medicine, and advancements in technology for cell culture and genetic engineering.
Which application held the maximum share in 2022?
The cancer application held the maximum share of the autologous cell therapy industry.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
